- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01896011
Effect of Teriparatide on Fracture Healing in Patients With Incomplete Atypical Femur Fractures
Effect of Teriparatide on Fracture Healing in Patients With Incomplete Atypical Femur Fractures: a Randomized Controlled Trial
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2C4
- University Health Network
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
i. Female or male; ii. Over the age of 30; iii. Experienced an incomplete AFF that satisfies the diagnostic criteria as set forth by the American Society for Bone and Mineral Research (ASBMR) International Task Force on AFFs:
- Atraumatic or low trauma incomplete stress fractures, defined as fractures sustained with minimal force, such as a fall from standing height;
- From distal to the lesser trochanter to proximal to the supracondylar flare along the femoral shaft.
- Radiographic confirmation of AFF features is required for a definitive diagnosis. Incomplete AFF features include cortical thickening, cortical beaking, and lucency line. Patients with cortical beaking without lucency line can be included.
Exclusion Criteria:
i. Peri-prosthetic fractures, ii. High trauma fractures, iii. Pathological fractures secondary to metastases or metabolic bone diseases other than osteoporosis, iv. Fractures that are not confirmed by radiological investigations, v. Contraindication to use of teriparatide such as:
- pregnant or nursing mothers, or women who are planning on pregnancy within 1 year of completing teriparatide therapy,
- hypersensitivity to teriparatide,
- severe renal impairment,
- multiple myeloma,
- active cancer in past 5 years (other than non-melanoma skin cancer),
- primary hyperparathyroidism,
- hypercalcemia,
- Paget's disease or other conditions that may increase the risk for osteosarcoma,
- Prior radiation therapy involving the skeleton, vi. Concomitant use of other osteoporosis therapies including bisphosphonates or denosumab (except calcitonin).
AFF patients with complete fractures on the contralateral side or patients with secondary osteoporosis will not be excluded.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Teriparatide 20 mcg daily
Teriparatide (Forteo) 20 mcg daily by injection pen for 12-24 months
|
Teriparatide 20 mcg injection pen
Other Names:
|
Placebo Comparator: Placebo
Placebo injection pen identical to active drug injection pen
|
Placebo 20 mcg injection pen
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in the modified The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)of the affected limb (the femur that has the incomplete AFF)
Time Frame: baseline to 12 months
|
baseline to 12 months
|
The proportion of patients requiring surgical intervention
Time Frame: baseline to 12 months
|
baseline to 12 months
|
Collaborators and Investigators
Investigators
- Study Director: Angela M Cheung, MD, PhD, University Health Network, Toronto
- Principal Investigator: Lianne E Tile, Md, MEd, University Health Network, Toronto
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 12-0170
- Control # 164050 (Registry Identifier: Health Canada BGTD)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Non Displaced Atypical Femoral Fractures
-
Meir Medical CenterUnknownDisplaced Subcapital Femoral FractureIsrael
-
Massachusetts General HospitalCompletedNon-displaced Scaphoid FracturesUnited States
-
University Health Network, TorontoRecruiting
-
Henry Ford Health SystemNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedOsteoporosis | Atypical Femoral Fractures | Prodromal Bone DeteriorationUnited States
-
Susan L. GreenspanEli Lilly and Company; University of PittsburghCompletedOsteoporosis | Atypical Femoral FractureUnited States
-
Washington University School of MedicineCompletedOsteoporosis | Atypical Femoral Fractures | Bisphosphonate Therapy
-
University Health Network, TorontoRecruitingAtypical Femur Fracture | Atypical Subtrochanteric Fracture | Osteoporosis With AFfCanada
-
McGill UniversityCanadian Institutes of Health Research (CIHR); McGill University Health Centre... and other collaboratorsRecruiting
-
University Hospital, GhentAZ Sint-Jan AVCompleted
-
Boston Children's HospitalCompletedDisplaced Forearm FracturesUnited States
Clinical Trials on Teriparatide 20 mcg
-
MedImmune LLCCompletedRespiratory Syncytial Virus (RSV)United States
-
University of North Carolina, Chapel HillNational Institute on Drug Abuse (NIDA); National Institute on Alcohol Abuse... and other collaboratorsCompletedHIV Infection | Hepatitis BBrazil, United States, South Africa
-
MedImmune LLCCambridge Antibody TechnologyTerminatedLeukemia, Lymphoma, Chronic Lymphocytic | Leukemia, Prolymphocytic Leukemia, Small | Lymphocytic Lymphoma, Moxetumomab PasudotoxUnited States, Poland
-
MedImmune LLCCompletedChronic Lymphocytic Leukemia | Non-Hodgkin LymphomaUnited States, Poland
-
Boehringer IngelheimCompletedPulmonary Disease, Chronic ObstructiveNetherlands
-
Radius Health, Inc.CompletedOsteoporosis | Postmenopausal OsteoporosisHong Kong, United States, Poland, Romania, Estonia, Czech Republic, Argentina, Brazil, Denmark, Lithuania
-
Bharat Biotech International LimitedCompleted
-
Massachusetts General HospitalCompletedPostmenopausal OsteoporosisUnited States
-
DSM Nutritional Products, Inc.Leatherhead Food ResearchCompletedOsteoporosis
-
Boehringer IngelheimCompletedPulmonary Disease, Chronic ObstructiveUnited States, Argentina, France, Greece, Korea, Republic of, New Zealand, Poland, Russian Federation, South Africa, Taiwan, Turkey, Ukraine, United Kingdom